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Abstract
Background: The aim of this study was to assess and compare the Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST 1.1) and the Choi criteria in evaluating the early response of advanced gastroenteropancreatic
neuroendocrine neoplasms (GEP-NENs) treated with sunitinib.
Methods: Eighteen patients with pathologically proven advanced GEP-NENs treated with sunitinib were
enrolled in the study. Pre- and post-treatment CT scans (plain, biphasic enhanced CT scan) were performed
on all patients. Changes in the target tumor size and density from pre-treatment to 1.4–3.1 months after
treatment were measured and recorded for each patient. Tumor responses were identified using RECIST
1.1 and Choi criteria. The time to tumor progression (TTP) for each patient was measured and compared
between groups using the Kaplan-Meier method.
Results: Among the 18 patients, 4 (22%) exhibited a partial response (PR), 9 (50%) exhibited stable disease
(SD), and 5 (28%) experienced progressive disease (PD), using RECIST 1.1. However, based on the Choi criteria,
8 (44%) patients exhibited a PR, 4 (22%) exhibited SD, and 6 (33%) experienced PD. According to RECIST 1.1,
the median TTP of PR, SD and PD group were 16.6, 10.8 and 2.3 months, respectively. The TTP of the PR
group was significantly longer than that of the PD group (P = 0.007) but insignificant when compared to the
SD group (P = 0.131). According to Choi criteria, the median TTP of PR, SD and PD group were not reached,
10.8 and 2.3 months, respectively. The TTP of the PR group was significantly longer than that of the SD
(P = 0.026) and PD groups (P < 0.001).
Conclusion: The Choi criteria appear to be more sensitive and more precise than RECIST 1.1 in assessing the
early response of advanced GEP-NENs treated with sunitinib.
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Background
Neuroendocrine neoplasms (NENs) comprise a wide
range of malignancies originating from the neuroendo-
crine cells throughout the human body that constitute
the endocrine system, or they may be derived from the
diffuse neuroendocrine system [1]. The incidence of
NENs in the last 30 years has significantly increased,
from an estimated incidence of 1.09/105 in 1973 to 5.05/
105 in 2004 [2]. Gastroenteropancreatic (GEP)-NENs are
the most common type of NENs, accounting for 67.5%
of all NEN cases [3]. These tumors are categorized as
functional or nonfunctional based on the presence of
hormone production, biological effects, and symptoms.
Approximately 20% of GEP-NENs have been estimated
to be functional [1–3]. Furthermore, WHO 2010 classifi-
cations distinguish GEP-NENs into well-differentiated
and poorly differentiated neoplasms. Well-differentiated
GEP-NENs are considered to be neuroendocrine tumors
and are graded as G1 (mitotic count <2 per 10 high
power fields (HPFs) and/or Ki67 ≤ 2%) or G2 (mitotic
count 2–20 per 10 HPFs and/or Ki67 3–20%). Poorly
differentiated GEP-NENs are considered to be neuroen-
docrine carcinomas and are graded as G3 (mitotic count
>20 per 10 HPFs and/or Ki67 > 20%) or mixed adeno-
neuroendocrine carcinomas [4].
Surgical resection alone can be curative in patients
with early-stage diseases [5, 6]. Unfortunately, more than
half of patients are diagnosed with advanced disease on
initial presentation which are not amenable to curative
resection alone at the time of diagnosis [1, 7]. Streptozo-
cin, used either alone or in combination with doxorubi-
cin and/or 5-fluorouracil, remains the only cytotoxic
chemotherapeutic agent approved for the treatment of
advanced GEP-NENs [8, 9]. However, only variable and
unsustainable outcomes have been observed, and its
high toxicity profile further limits its clinical use [10].
For functional tumors, somatostatin analogues have
been widely used for symptomatic relief, but they have
limited antitumor activity [11, 12]. Newly developed tar-
geted treatments, such as sunitinib malate (SUTENT;
Pfizer Inc., New York, NY, USA), which potently inhibits
a number of receptor tyrosine kinases, including vascu-
lar endothelial growth factor receptors (VEGFRs) 2 and
3, platelet-derived growth factor receptors (PDGFRs) α
and β and the stem-cell factor receptor (c-kit) [13, 14],
appear to be effective in the treatment of GEP-NENs. It
is believed that tissues from these tumors exhibit wide-
spread expression of these receptors, and inhibition by
sunitinib blocks signal transduction, thereby reducing
tumor growth, progression and metastasis [15, 16].
Sunitinib malate has shown clear clinical benefits for ad-
vanced GEP-NENs in phase II and III trials [17–19].
Evaluating tumor response is an arduous task due to the
increasing use of sunitinib in the treatment of GEP-
NENs. Response Evaluation Criteria in Solid Tumors
(RECIST) is a well-established tool for the assessment of
tumor response in clinical trials and one of the most
commonly used sets of criteria that only considers long-
term changes as its parameters [20]. However, recent
studies have suggested that the introduction of targeted
therapies may have no major effect on tumor size, des-
pite reducing tumor vascularization and, consequently,
tumor density [21, 22]. Thus, RECIST may significantly
underestimate the tumor response to targeted therapies
[23]. The ongoing challenge of evaluating the tumor re-
sponse to targeted therapies prompted Choi et al. to de-
velop composite criteria that integrate changes in both
tumor size and density to evaluate the tumor response to
imatinib, another targeted agent used in gastrointestinal
stromal tumors (GISTs). The Choi criteria appeared to be
more accurate in predicting drug efficacy than RECIST for
GISTs treated with imatinib [24]. Similar findings have been
observed in other solid tumors, such as hepatocellular car-
cinoma (HCC) and renal cell carcinoma [25–28]. Several
diagnostic techniques have been widely used for monitoring
the course of treatment and surveillance of GEP-NENs, in-
cluding high-frequency or contrast-enhanced ultrasound
echography, dynamic contrast-enhanced magnetic res-
onance imaging, and 18-fluorodeoxyglucose positron
emission tomography scanning. The main drawbacks of
these investigations include their cost, reproducibility,
inter-observer variability, and limited availability [24].
Due to its panoramic capabilities and high spatial reso-
lution, only contrast-enhanced computed tomography
(CT) can be considered a reliable method for assessing
both tumor size and tissue density [24].
Faivre S,and Dreyer C have suggested that Choi
criteria might be considered as an alternative to RECIST
to evaluate the effects of sunitinib in patients with ad-
vanced pancreatic neuroendocrine tumors with a small
sample size (n = 10) did not enrolled the midgut NENs
[25, 26]. In this study, we aimed to assess whether the
Choi criteria could be used as a tool for quantitatively
evaluating tumor response as an alternative to RECIST
in advanced GEP-NENs treated with sunitinib.
Methods
Patients and clinical follow-up
In this retrospective study, patients with pathologically
confirmed advanced GEP-NENs treated with sunitinib in
our institution between January 2010 and October 2015
were selected. The trial was approved by the Institutional
Review Board of Sun Yat-Sen University, and all patients
enrolled in this study provided written informed consent
for the research study protocol. All methods were carried
out in accordance with the approved guidelines. Add-
itional inclusion criteria involved the following: a minimal
cumulative duration of 4 weeks of sunitinib treatment in
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patients with adequate hematologic, hepatic, and renal
function. Patients underwent baseline thoracic, abdominal
and pelvic CT scans within 3 weeks before sunitinib ad-
ministration and an early evaluation of the tumor with a
second CT scan within 1.4–3.1 months after the initiation
of sunitinib treatment and every 2–3 months thereafter.
Patients with non-evaluable lesions (largest diameter of
the target lesion smaller than 1.0 cm) or whose scans were
performed outside of the predefined interval were ex-
cluded. Patients with missing data due to poor follow-up
compliance or premature death before the early evaluation
were also excluded.
Treatment
Patients received a continuous daily administration of
sunitinib at an initial dose of 37.5 mg and were
followed-up with on a monthly basis to assess clinical
response and tolerance. A reduction in the dose to
25 mg was permitted in patients experiencing severe
adverse events. Treatment was continued until con-
firmed disease progression was documented, unaccept-
able adverse events were observed, or premature death
has occurred. Tumor progression was identified on the
basis of the following CT findings: the appearance of
new lesions or metastasis, the appearance of new intra-
tumoral nodules, or an increase in overall tumor size of
greater than 20% [20].
Imaging techniques
All patients received enemas the night before their CT
scans and fasted for a minimum of 6–8 h prior to the
scans. All patients were given 1.6–2.0 L of 2.5% mannitol
one hour before and 0.4–0.5 L at 45, 30, and 15 min
before CT to ensure adequate bowel distension. The rec-
tum was also distended using a 2.5% mannitol enema.
Scans of the chest, abdomen, and pelvis were performed
using a multi-slice CT scanner (Aquilion64, Toshiba
Medical Systems, Tokyo, Japan) with the following scan
parameters: tube voltage – 120 kV; tube current –
200 mA; beam collimation – 6 × 0.5 mm; slice thickness
– 0.5 mm; slice increments – 0.5 mm; and pitch – 0.9.
After the non-contrast scan, iodinated contrast (Ultravist
300, Bayer Schering, Berlin, Germany) at a concentration
of 300 mg iodine/mL was administered at a flow rate of
3–4 ml/s via a needle cannula placed in the antecubital
vein using an automatic injector with a volume of
1.5 mL/kg, followed by a 40-mL bolus of saline solution.
After unenhanced scanning, arterial and portal venous
phase acquisitions were obtained at 35 s and 65 s
after the initiation of contrast medium injection, re-
spectively. The unenhanced and portal venous phase
scanning were performed on the chest, abdomen and
pelvis, and the arterial phase scanning was only per-
formed on the abdomen.
Imaging analysis
At the end of the study, a radiologist with 14 years of
experience in abdominal imaging who was blinded to
the clinical data reviewed the baseline and all follow-
up CT images independently in a randomized order.
The CT images were analyzed according to the fol-
lowing parameters: target lesion detection, target le-
sion size (in centimeters) and density in Hounsfield
Units (HU), and the TTP.
Target lesions
In the baseline CT images, the target lesion was required
to be ≥1.0 cm in the largest dimension according to the
selection criteria. Malignant thrombosis, malignant
ascites or pleural effusion (confirmed by cytological
examination of the fluid), and a lymph node with a short
diameter ≤1.5 cm were considered to represent non-
target lesions. A maximum of two lesions per organ and
five total lesions per patient were selected according to
RECIST version 1.1 recommendations [20]. For the Choi
criteria, the same target lesions selected in RECIST
version 1.1 were used [23, 24].
Tumor size
The lymph nodes were measured in short axis and pri-
mary tumors and metastases were measured in long axis.
Tumor size was measured using the longest cross-
sectional dimension for each lesion at each time point
using an advanced workstation (Vitrea 2, Toshiba Med-
ical System, Tokyo, Japan). In patients with more than
one identified target lesion, the sum of the longest diam-
eters of each target lesion in each patient was computed.
Then, the percent change in tumor size recorded be-
tween pre-treatment and the early evaluation was com-
puted for each patient. Figure 1a displays a typical
example of a tumor size evaluation.
Tumor density
The portal venous phase was employed for tumor density
measurements. Using the advanced workstation (Vitrea2,
Toshiba Medical System, Tokyo, Japan), the CT attenu-
ation coefficient of each lesion was measured in HU by
circumscribing the margin of the entire tumor in the axial
plane as a region of interest. When the density evalu-
ation was performed on more than one target lesion,
the global density of the target lesions was calculated.
The percent change in tumor density between pre-
treatment and the early evaluation was again com-
puted for each patient. Figure 1b displays a typical
example of a tumor density evaluation.
TTP
TTP was defined as the time from treatment to the
first evidence of tumor progression or to the last CT
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scan for those with no tumor progression. Tumor
progression was identified on the basis of the follow-
ing CT findings: the appearance of new lesions or
metastasis, the appearance of new intratumoral nod-
ules, or an increase in overall tumor size of greater
than 20% [20].
Tumor response assessment according to RECIST version
1.1 and the Choi criteria
Using the parameters mentioned above, we evaluated each
individual’s responses and grouped them as complete re-
sponse (CR), PR, SD or PD according to RECIST version
1.1 and the Choi criteria [20, 24] (Table 1).
Fig. 1 Example of evaluating percentile change in tumor size and density. Pre-treatment and post-treatment CT scans showing shrinkage
of hepatic metastases from a pancreatic neuroendocrine tumor in one’s fifties, the percentile change of tumor size was (8.0–11.9)/11.9 ×
100% = −33% (a). In another lesion in the same patient, the hepatic metastases appeared more heterogeneous, with high vascularization
prior to treatment. Sunitinib induced a large area of tumor hypodensity, suggesting tumor necrosis, the percentile change of tumor attenuation was
(108–121)/121 × 100%= −11% (b). In patients with more than one target lesion, the sum of the longest diameters/density of each target lesion in each
patient was computed
Table 1 Comparison of RECIST version 1.1 and the Choi criteria
RECIST version 1.1 Choi criteria
CR Disappearance of all lesions
No new lesions
Disappearance of all lesions
No new lesions
PR A decrease in sizea of ≥30% A decrease in sizea of ≥10% or a decrease in tumor density
(HU) of ≥15% in CT
No new lesions
No obvious progression of immeasurable disease
SD Neither sufficient shrinkage to qualify for PR
nor a sufficient increase to qualify for PD
Does not meet the criteria for CR, PR, or PD
No symptomatic deterioration attributable to tumor progression
PD An increase in sizea of ≥20%
New lesions
New intratumoral nodules or increase in the size of the
existing intratumoral nodules
An increase in tumor sizea of ≥10% and does not meet the criteria
for PR based on tumor density (HU) in CT
New lesions
New intratumoral nodules or an increase in the size of the existing
intratumoral nodules
aSum of the diameters of the target lesions defined in RECIST version 1.1 [20]
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Statistical analysis
The percent changes in tumor size and density were cal-
culated to evaluate treatment response using both
RECIST version 1.1 and the Choi criteria. The Wilcoxon
rank-sum test (paired samples), the Kruskal-Wallis test
(three independent samples) and the Mann–Whitney U
test (two independent samples) were used for intragroup
comparisons. To evaluate the ability of RECIST version
1.1 and the Choi criteria to predict prognosis, TTPs were
compared between the respective groups using the
Kaplan-Meier method. Kaplan-Meier curves were
compared using the log-rank (Mantel-Cox) test, and all
statistical analyses were performed using SPSS (Version
19.0; IBM Corp., Armonk, NY, USA). A difference with
a P value of <0.05 was considered statistically significant.
Results
Study population
During the recruitment period, a total of twenty patients
were treated for advanced GEP-NENs using sunitinib at
our institution. A total of 18 patients met the eligibility
criteria and were included in the study. The remaining 2
patients were excluded from the analysis either because
of non-evaluable CT scans or evaluations performed out-
side the predefined interval. In total, 44 target lesions
were measured in 18 patients (median, 2 lesions per pa-
tient; range, 1–4 lesions per patient). The demographic
and baseline characteristics of the patients are presented
in Table 2.
Among the enrolled 18 patients, five patients had dose
reduced to 25 mg, the main adverse events resulted in the
reduction of dosage included hand-foot syndrome and
skin toxicity (n = 3), thrombocytopenia (n = 1) and neutro-
penia (n = 1). In the patient with thrombocytopenia, after
dosage reduction to 25 mg/day, the patient still demon-
strated persistent thrombocytopenia and subsequent treat-
ment failure after 1.0 months. This patient demonstrated
evidence of progressive disease at first follow up CT scan
performed 1.4 months post treatment.
Early assessment of changes in tumor size and density
In the 18 evaluable patients, the total tumor size in each
patient ranged from 2.6 to 28.5 cm (median, 13.7 cm)
before treatment and from 3.2 to 30.0 cm (median,
10.9 cm) at the first evaluation after treatment. Tumor
density ranged from 63 to 478 HU (median, 179 HU)
before treatment and from 68 to 453 HU (median, 144
HU) at the first evaluation after treatment. No signifi-
cant difference (Z = −0.348,P = 0.727) in tumor size was
observed between the baseline and the first evaluation.
However, a significant decrease (Z = −2.309,P = 0.021) in
tumor density was detected among the evaluable lesions.
Figure 2 shows the percent change in tumor size and
density measured via CT scans at baseline and at the
first evaluation after treatment with sunitinib for all eva-
luable patients.
Early response assessed using RECIST 1.1 and the Choi
criteria
Tumor response to sunitinib was evaluated using RECIST
1.1 and the Choi criteria. Among the 18 patients evaluated
in this trial, no patient demonstrated CR after treatment
with sunitinib, 4 patients (22.2%) demonstrated PR, while
Table 2 Patients and baseline characteristics
Characteristic
Age (yr), n (%)
Median 47.5
Range 28–61




Unknown origin 3 (16.7)
Site of target lesions, n (%)
Pancreas (primary tumor) 11 (25.0)
Liver 25 (56.8)
Mesenteric lymph node 1 (2.3)
Retroperitoneal lymph node 3 (6.8)
Pelvic cavity 4 (9.1)
Pathological classification, n (%)
Grade 1 2 (11.1)
Grade 2 14 (77.8)
Grade 3 2 (11.1)
Tumor functionality, n (%)
Nonfunctioning 16 (88.9)
Functioning 2 (11.1)




Transarterial chemoembolization 1 (5.6)
Transarterial chemoembolization & Octreotide 1 (5.6)
Duration of sunitinib (months)
Median 6.8
Range 1.0–22.7
Time between initiation and first evaluation (months)
Median 2.3
Range 1.4–3.1
Duration of follow-up (months)
Median 17.3
Range 4.3–47.9
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9 patients (50.0%) demonstrated SD, and 5 patients
(27.8%) demonstrated PD according to RECIST 1.1. Based
on the Choi criteria, 8 (44.4%) of 18 evaluable patients
demonstrated PR (Figs. 3 and 4), 4 patients (22.2%) dem-
onstrated SD and 6 patients (33.3%) demonstrated PD.
Among the patients classified as showing PD by RECIST
1.1, 2 developed new lesions, and the other 3 showed an
increase in tumor size of greater than 20% according to
the various criteria.
The median changes in tumor size and density in the
PR, SD and PD groups according to both RECIST 1.1
and the Choi criteria are shown in Table 3 (placed at the
end of the document text file). The changes in tumor
size were significantly different in the three groups
Fig. 2 Waterfall plot of the percent change in tumor size (a) and density (b) at the first evaluation after sunitinib treatment
Fig. 3 A primary pancreatic neuroendocrine tumor with multiple hepatic metastases (G2) in one’s fourties. (a) Pre-treatment CT scan showing a
large mass in the pancreatic body with a heterogeneous, hyperdense tumor (white arrow, size: 5.5 cm, density: 91 HU). (b) CT scan obtained
2.8 months after treatment of sunitinib showing that the lesion had become significantly smaller in size and more hypodense (white arrow, size:
2.5 cm, density: 44 HU). The percent change in tumor size and density was 55% and 52%, respectively, which was classified as PR by both the
Choi criteria and RECIST. Samples obtained through endoscopic ultrasound-guided fine needle tissue acquisition before treatment showing a
large trabecular structure, moderate cell atypia (c, original magnification, ×200, hematoxylin-eosin staining) and intense immunoreactivity for
VEGFR2 (d, original magnification, ×200, IHC staining)
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according to both RECIST 1.1 and the Choi criteria
(P < 0.05). The differences observed in the change of
tumor density were statistically significant according
to the Choi criteria (P = 0.042), but not according to
RECIST 1.1 (P = 0.119).
Assessment of TTP according to RECIST 1.1 and the Choi
criteria
During the trial, we monitored tumor progression was
observed in twelve patients. The remaining 6 patients
(33.3%) exhibited no evidence of tumor progression. The
median TTP of these18 patients was 10.8 months. A
significant difference in TTP was observed in the PR,
SD and PD groups when using both sets of criteria
(P < 0.001, Fig. 5). Based on the RECIST 1.1, the me-
dian TTP of PR, SD and PD were 16.6 months,
10.8 months and 2.3 months, respectively. According
the Choi criteria, the median TTP of PR, SD and PD
group were not reached, 10.8 months and 2.3 months,
respectively. The results of secondary analyses for
TTP showed that according to RECIST 1.1, there was
a significant difference in TTP between the PR and
PD groups (P = 0.007) and between the SD and PD
groups (P < 0.001), but there was no significant differ-
ence between the PR and SD groups (P = 0.131).
Based on the Choi criteria, the TTP of the PR group
was significantly longer than those observed in the
SD (P = 0.026) and PD groups (P < 0.001), and the
TTP of the SD group was significantly longer than
that in the PD group (P = 0.006). Table 4 showed the
percentile change of tumor size, tumor density, early
response to Sunitinib by RECIST 1.1 and Choi cri-
teria, and TTP of each patient.
Discussion
The response of solid tumors to treatment has tradition-
ally been evaluated using RECIST 1.1. According to
RECIST 1.1, PR corresponds to a >30% decrease in the
sum of the maximum diameters of the target lesions,
which is the current standard for assessing the re-
sponse of solid tumors to anticancer therapy [20].
However, for targeted therapies, which generally re-
duce tumor vascularization, subsequently inducing ne-
crosis and cystic degeneration, the change in tumor
density can also be measured from clinical images as
a parameter for evaluating the response to targeted
therapies [22]. Nevertheless, changes in tumor density
may have no major effect on tumor size during
targeted therapy and are frequently categorized as SD
when using RECIST. Therefore, the application of
RECIST which fails to identify clinical response to
targeted therapies in this group of patients carries the
risk of prematurely terminating the use of active tar-
geted drugs. The Choi criteria, which incorporate
changes in both tumor density and size measured via
CT, have been demonstrated to be more sensitive and
accurate than RECIST for predicting imatinib efficacy
in GISTs [23, 24]. Faivre S, et al. have reported the
use of the Choi criteria as an alternative to RECIST
for evaluating the effects of sunitinib in patients with
advanced pancreatic NENs only, however, it was not
used to evaluate midgut NENs in that study [25, 26].
The present study was conducted to compare the two
sets of criteria based on the data obtained from a
Fig. 4 A pancreatic neuroendocrine tumor (G2) with retroperitoneal lymph node metastases in one’s fifties. The pre-treatment CT scan showed
(a) retroperitoneal fusion nodules with a relatively low density (white arrows, size: 2.0 cm, density: 82 HU) in front of the abdominal artery. (b) The
nodules exhibited a slight reduction in size and an obvious reduction in density (white arrows, size: 1.9 cm, density: 56 HU) at the first evaluation
after treatment with sunitinib. The percent change in tumor size and density was 5.0% and 31.7%, respectively. This patient was classified as PR
according to the Choi criteria but as SD based on RECIST
Table 3 Median changes in tumor size and density according
to RECIST 1.1 and the Choi criteria in evaluable patients (%)
Parameter RECIST 1.1 Choi criteria
Size Density Size Density
PR −43.4 −17.8 −24.9 −16.8
SD 3.5 −5.8 3.8 −5.0
PD 21.0 1.2 18.2 3.2
Z value 13.888 4.256 13.263 6.352
P value 0.001 0.119 0.001 0.042
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homogenous group of patients with advanced GEP-
NENs treated with sunitinib. A comparison of the
Choi criteria with RECIST demonstrated that the
Choi criteria were more precise in assessing the early
response of GEP-NENs to sunitinib.
In the present study, both tumor size and density were
decreased after treatment with sunitinib. No statistically
significant difference was observed in tumor size before
and after treatment (Z = −0.348, P = 0.727), whereas the
difference in tumor density before and after treatment
was statistically significant (Z = −2.309, P = 0.021).
Similar results have been reported previously for HCC
[29, 30]. Faivre et al. observed the striking appearance of
large areas of tumor hypodensity during treatment with
sunitinib in HCC, despite limited changes in tumor size
[30]. Zhu and colleagues reported that sunitinib signifi-
cantly reduced intratumoral vascularization, leading to
significant changes in the transfer constant Ktrans, a
surrogate endpoint for vessel leakage [30, 31]. These
features are believed to reflect the inhibitory effects of su-
nitinib on vascular endothelial cell VEGFR expression and
on tumor pericyte PDGFR expression, resulting in dis-
rupted, congested, tortuous, and leaking tumor vessels as-
sociated with necrotic areas in the tumor, rather than
Fig. 5 Kaplan-Meier analyses of the TTP in the PR, SD and PD groups, as classified according to RECIST 1.1 (a) and the Choi criteria (b)
Table 4 Early evaluation of tumor response to sunitinib by RECIST 1.1 and Choi criteria
No. of patient Change in tumor size (%) Change in tumor density (%) RECIST 1.1 response Choi response TTP (m)
1 −34 −15 PR PR 16.6
2 −42 −21 PR PR 6.4
3 −45 11 PR PR 18.5
4 −50 −54 PR PR 13.0
5 −15 3 SD PR 7.4
6 5 −15 SD PR 22.8
7 −6 −18 SD PR 20.5
8 −9 −34 SD PR 2.4
9 −3 −8 SD SD 10.8
10 5 −5 SD SD 15.1
11 4 −3 SD SD 5.9
12 3 −5 SD SD 12.6
13 11 5 SD PD 5.7
14 11 −1 PDa PD 1.4
15 27 9 PD PD 3.1
16 15 −4 PDa PD 2.3
17 24 1 PD PD 2.1
18 21 8 PD PD 2.5
aThe Progressive Disease of RECIST version 1.1 was the result of new lesions at the first follow up by CT scan, rather than the increase of tumor size
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significant shrinkage of tumor cells [18], which may indi-
cate that a reduction in tumor density is a more sensitive
parameter than tumor size in evaluating the early re-
sponses to sunitinib treatment.
According to both RECIST 1.1 and the Choi criteria,
the differences in the change in tumor size observed in
the PR, SD and PD groups were statistically significant
(P < 0.005). The differences in the change in tumor dens-
ity among the three groups based on RECIST 1.1 were
not statistically significant (P = 0.119), but a significant
difference in the change in tumor density was observed
according to the Choi criteria (P = 0.042). These results
indicate in addition to RECIST 1.1 where treatment
reponse is based solely on change in tumor size, the
Choi criteria also reflect differences in histological com-
position during the treatment of GEP-NENs with suniti-
nib, which clearly originates from the definitions of
RECIST and the Choi criteria [20, 24].
The Choi response criteria, which incorporate
changes in both tumor density and size observed in
contrast-enhanced CT scans, classified twice as many
of the 18 GEP-NEN patients as PR (44.4%) compared
with RECIST 1.1 (22.2%). Moreover, the TTP was
significantly longer in patients classified as PR accord-
ing to the Choi criteria than in those classified as SD
(P = 0.026) and PD (P < 0.001). According to RECIST
1.1, statistically significant differences in TTP were
observed between the PR and PD groups (P = 0.007)
and between the SD and PD groups (P < 0.001). How-
ever, using RECIST 1.1, TTP was not significantly
longer in patients classified as PR than in those clas-
sified as SD (P = 0.131). These results suggested that
patients with advanced GEP-NENs who were catego-
rized into the PR group according to the Choi criteria
during the early tumor evaluation experienced better
outcomes than those in the SD group. This finding
is consistent with the ones suggested Benjamin and
Choi et al., who also raised this issue regarding the
inadequacy of RECIST in identifying responding
tumors. This limitation of RECIST may be due to
the way sunitinib functions as an antiangiogenic
agent [23, 24].
Unlike RECIST 1.1, the Choi criteria do not provide
clear definitions for evaluating TTP in patients. There-
fore, in this study, we were unable to define TTP accord-
ing to the Choi criteria. At the end of this trial, 12
patients demonstrated evidence of tumor progression,
and the TTP could not be established in 6 patients, as
illustrated in the results. It is likely that RECIST 1.1 and
the Choi criteria would converge in defining similar
rates of progression. Furthermore, in the work reported
by Choi and colleagues, who compared the Choi criteria
and RECIST 1.1 in evaluating the efficacy of imatinib
against metastatic GISTs, the TTP was defined as the
same rate of disease progression as in RECIST 1.1 in
both groups [24].
Another limitation of this trial include small sample
size which may result in certain degree of research bias.
However, this study remains significant as it may help to
identify the need to cooperate a better criteria for
clinical evaluation of tumor response.
Conclusion
In conclusion, the Choi criteria appears to be more
appropriate than RECIST 1.1 in identifying clinical
responses as longer TTP observed in Choi represents
better efficacy of sunitinib in advanced GEP-NENs. The
limitations of a small sample size and intermediate
follow-up period may result in certain degree of research
bias. Future studies with large sample sizes and long
enough follow-up times should be conducted to further
explore the most appropriate criteria in evaluating the
tumor response to sunitinib treatment.
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